Athira Begin Period Cash Flow vs Depreciation Analysis
ATHA Stock | USD 0.58 0.03 5.45% |
Athira Pharma financial indicator trend analysis is way more than just evaluating Athira Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Athira Pharma is a good investment. Please check the relationship between Athira Pharma Begin Period Cash Flow and its Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.
Begin Period Cash Flow vs Depreciation
Begin Period Cash Flow vs Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Athira Pharma Begin Period Cash Flow account and Depreciation. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Athira Pharma's Begin Period Cash Flow and Depreciation is 0.9. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Depreciation in the same time period over historical financial statements of Athira Pharma, assuming nothing else is changed. The correlation between historical values of Athira Pharma's Begin Period Cash Flow and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Athira Pharma are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Begin Period Cash Flow i.e., Athira Pharma's Begin Period Cash Flow and Depreciation go up and down completely randomly.
Correlation Coefficient | 0.9 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Athira Pharma value has been used up. For tax purposes Athira Pharma can deduct the cost of the tangible assets it purchases as business expenses. However, Athira Pharma must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Most indicators from Athira Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Athira Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.As of December 22, 2024, Selling General Administrative is expected to decline to about 17.8 M. Issuance Of Capital Stock is expected to grow at the current pace this year
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 479K | 845K | 969K | 631.1K | Cost Of Revenue | 479K | 1.0M | 969K | 899.2K |
Athira Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Athira Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Athira Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.2M | 279.6M | 332.0M | 258.2M | 160.2M | 190.1M | |
Short Long Term Debt Total | 1.6M | 1M | 1.9M | 1.9M | 1.6M | 1.6M | |
Other Current Liab | 852K | 3.0M | 8.1M | 18.3M | 28.0M | 29.4M | |
Total Current Liabilities | 1.3M | 4.4M | 9.3M | 21.4M | 28.8M | 30.3M | |
Total Stockholder Equity | (19.7M) | 274.3M | 321.1M | 235.1M | 130.2M | 169.8M | |
Net Tangible Assets | (19.7M) | 274.3M | 321.1M | 235.1M | 270.4M | 175.1M | |
Net Debt | (503K) | (59.6M) | (108.6M) | (94.1M) | (89.0M) | (93.4M) | |
Retained Earnings | (21.1M) | (41.0M) | (95.9M) | (191.5M) | (309.2M) | (293.7M) | |
Accounts Payable | 421K | 1.2M | 567K | 2.5M | 129K | 122.6K | |
Cash | 2.1M | 60.6M | 110.5M | 96.0M | 90.6M | 66.6M | |
Non Current Assets Total | 29K | 87.2M | 71.2M | 50.6M | 5.5M | 5.2M | |
Non Currrent Assets Other | 29K | 132K | 56K | 475K | 1.1M | 1.1M | |
Other Assets | 29K | 84.6M | 5.3M | 0.0 | 1.0 | 0.95 | |
Cash And Short Term Investments | 2.1M | 184.7M | 253.8M | 200.3M | 147.4M | 145.4M | |
Net Receivables | 7K | 1.3M | 2.3M | 1.2M | 1.6M | 1.2M | |
Common Stock Shares Outstanding | 32.6M | 32.5M | 36.9M | 37.7M | 38.0M | 33.7M | |
Short Term Investments | 0.0 | 124.1M | 143.2M | 104.4M | 56.8M | 78.8M | |
Liabilities And Stockholders Equity | 2.2M | 279.6M | 332.0M | 258.2M | 160.2M | 190.1M | |
Non Current Liabilities Total | 20.6M | 876K | 1.6M | 1.6M | 1.2M | 1.2M | |
Other Current Assets | 97K | 6.4M | 4.7M | 6.0M | 5.7M | 4.2M | |
Other Stockholder Equity | 1.4M | 315.3M | 417.4M | 428.6M | 439.7M | 294.0M | |
Total Liab | 21.9M | 5.3M | 10.9M | 23.0M | 30.1M | 20.4M | |
Net Invested Capital | (18.2M) | 274.3M | 321.1M | 235.1M | 130.2M | 170.2M | |
Total Current Assets | 2.2M | 192.3M | 260.8M | 207.5M | 154.7M | 150.8M | |
Non Current Liabilities Other | 1.0M | 876K | 1.6M | 1.6M | 1.8M | 1.3M | |
Net Working Capital | 887K | 187.9M | 251.5M | 186.1M | 125.9M | 138.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.48) | Return On Equity (0.85) |
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.